Enjoy complimentary customisation on priority with our Enterprise License!
The global infantile spasms therapeutics market size is estimated to grow by USD 89.61 million at a CAGR (Compound Annual Growth Rate) of 5.41% between 2023 and 2028.
Ongoing research in neurology and epilepsy is driving the development of new therapeutic possibilities in the market for infantile spasms therapeutics. Collaboration between pharmaceutical companies and academic institutes fosters a conducive climate for breakthroughs, fostering multidisciplinary investigation. As a result, the market benefits from a steady infusion of cutting-edge treatment choices, which improves the overall efficacy and specificity of infantile spasm therapeutics. This dynamic landscape puts continuing neurology and epilepsy research as a critical driver for revolutionary advances in the treatment.
To learn more about this report, Download Report Sample
The market share growth by the parenteral segment will be significant during the forecast period. In the market, the parental route of administration is developing as a major approach, providing direct and efficient drug delivery. Parenteral formulations such as intravenous and intramuscular injections, ensure rapid and exact medication distribution, which is essential in the treatment.
Get a glance at the market contribution of various segments Download PDF Sample
The parenteral segment was the largest and was valued at USD 225.03 million in 2018. Parenterally provided drugs include Adrenocorticotropic hormone (ACTH) and vigabatrin, which are routinely used to treat infantile spasms. The parenteral approach improves bioavailability, allowing for faster therapeutic effects. This trend corresponds to the critical need for rapid intervention in the treatment of infantile spasms, emphasizing the importance of parenteral administration in delivering therapeutics directly into the bloodstream for optimal efficacy, making it a pivotal and increasingly preferred route of administration in the evolving landscape of Infantile Spasms Therapeutics. Conclusively, the increasing prevalence of parental routes for the administration is expected to drive the growth of the market during the forecast period.
Anticonvulsants are a leading drug class in the market, playing a critical role in controlling and reducing spasms caused by this neurological condition. ACTH, vigabatrin, and oral corticosteroids are examples of drugs in this class that have shown success in reducing seizures. As anticonvulsants remain an essential drug class in Infantile Spasms Therapeutics, developments and innovations within this drug class are projected to fuel continued expansion of the anticonvulsants segment during the forecast period, providing superior management options for people suffering from this ailment. This, in turn, will drive the growth of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The market in North America has witnessed a significant growth potential in recent years. The high prevalence of infantile spasms, a well-established healthcare infrastructure, and increased awareness about early diagnosis and intervention are driving this expansion. The region's powerful R&D ecosystem encourages therapeutic approach innovation. Leading pharmaceutical businesses such as Mallinckrodt and H Lundbeck actively contribute to regional market growth by developing new drugs. Collaborations among research institutions, healthcare providers, and advocacy groups improve the market landscape even more.
However, challenges include the need for improved awareness as well as potential regulatory stumbling blocks. The North American market is positioned for sustained expansion, offering advanced treatment options for affected individuals, thanks to a patient-centric approach, ongoing research endeavors, and an emphasis on precision medicine. Owing to such factors. The regional market is expected to grow at a significant rate during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market growth analysis report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Amneal Pharmaceuticals Inc. - The company offers infantile spasms therapeutics such as vigabatrin tablet used as monotherapy to treat infantile spasms in infants 1 month to 2 years.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the trends, and challenges.
Growing interest in gene therapy is one of the major market trends. With increased interest in gene therapy as a viable treatment technique, the market is experiencing a major development. By directly treating the genetic causes underlying infantile spasms, gene therapy provides focused and personalized therapeutic alternatives. Researchers are actively investigating strategies for modifying or replacing faulty genes related to the disorder. For example, ongoing research is focusing on changing certain genes to modulate neural activity and reduce spasms. This movement represents a paradigm shift towards precision medicine, in which therapies are personalized to patients' unique genetic composition.
Further, the pursuit of gene therapy improvements holds the promise of more effective and precisely customized solutions for infantile spasms, showing a revolutionary potential in therapeutic interventions and offering better outcomes for those affected by this neurological illness. Hence, the growing interest in gene therapy is expected to drive the growth of the market during the forecast period.
Lack of awareness about infantile spasms among healthcare professionals and caregivers is an emerging challenge. The market faces significant challenges due to a lack of understanding regarding infantile spasms among healthcare professionals and caregivers. This lack of awareness can lead to delayed diagnosis and treatment initiation, both of which have a significant impact on patient outcomes. Healthcare providers may misread symptoms, resulting in misdiagnosis or delayed diagnosis, whereas caregivers may fail to recognize the importance of obtaining quick medical help.
However, to address this issue, comprehensive educational initiatives aimed at healthcare professionals, caregivers, and the general public must be implemented to raise awareness, promote early detection, and facilitate timely access to Infantile Spasms Therapeutics, ultimately improving patient care and overall treatment effectiveness. Owing to all such factors, the market is expected to witness a hindrance in growth during the forecast period.
The market growth analysis report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The infantile spasms therapeutics market addresses conditions like West syndrome, triggered by factors such as brain tumors, birth injuries, or genetic abnormalities. With ongoing product innovation and government initiatives, research and development activities propel the market forward. Pipeline drugs offer hope, albeit with considerations like treatment costs and regulations. Dosage precision and suitable distribution channels ensure efficacy, with end-users benefiting from improved healthcare expenditure allocation. Regions like Mexico witness notable developments in this sector, reflecting a global commitment to combatting infantile spasms and providing comprehensive care for affected children, highlighting the importance of concerted efforts in advancing therapeutic solutions.
The market research and growth report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Infantile Spasms Therapeutics Market Scope |
|
Market Report Coverage |
Details |
Page number |
154 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.41% |
Market Growth 2024-2028 |
USD 89.61 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.52 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Amneal Pharmaceuticals Inc., Cipla Ltd., Endo International Plc, H Lundbeck AS, Hetero Labs Ltd., Intas Pharmaceuticals Ltd., Jazz Pharmaceuticals Plc, Mallinckrodt Plc, Marinus Pharmaceuticals Inc., MSN Laboratories, Ovid Therapeutics Inc., Sanofi SA, SGPharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Anavex Life Sciences Corp., Genix Pharma Pvt. Ltd., Jolly Healthcare, and ORPHELIA Pharma |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our market forecasting report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.